Abstract
In this business case, Jhpiego proposes a market shaping strategy to improve the quality of oxytocin. The strategy suggests that international partners work with national procurement agencies to improve procurement guidelines and procedures to ensure that only quality drugs are accepted into the countries, and to ensure the cold chain for oxytocin is strengthened. International partners can also work with National Drug Regulatory Agencies (NDRAs) and others to increase awareness about quality issues with oxytocin. With stricter enforcement of national guidelines, and routine quality audits of drugs in the country, procurers will ensure the drugs they procure are quality assured. If there is a WHO-prequalified drug, this will assist procurement agencies in ensuring they are making the right selection, but quality can be assured in other ways.
